FDA D.I.S.C.O. Burst Edition: FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma

FDA D.I.S.C.O. Burst Edition: FDA approves te...

U.S. Food and Drug Administration, Center for Drug Evaluation and ResearchU.S. Food and Drug Administration, Center for Drug Evaluation and Research

Up next

FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer

Listen to a soundcast of the March 3, 2023, FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer. 

 . 4min 30sec
FDA D.I.S.C.O. Burst Edition: FDA approval of Jemperli (dostarlimab-gxly) for dMMR endometrial cancer

Listen to a soundcast of the February 9, 2023, FDA approval of Jemperli (dostarlimab-gxly) for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen. 

 . 3min 30sec

Recommended Episodes

DFMO FDA Approval with Dr. Nicole Drezner
This Week in Pediatric Oncology

In this episode Dr. Timothy Cripe and Dr. Brenda Weigel are joined by FDA's Dr. Nicole Drezner, pediatric oncologist and the Deputy Division Director of the Division of Oncology 2 who led the FDA review and publication on the approval of DFMO. Listen in on the discussion surround ...  Show more

 . 35min 23sec
Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill
BackTable Urology

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

 . 1h 0min
179. Back to Basics - Metastatic NSCLC feat. EGFR and ALK Driver Mutations
Oncology for the Inquisitive Mind

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? ...  Show more

 . 24min 44sec
FDA Approved Therapy for SOD1 Associated ALS
Neurology® Podcast

Dr. Gordon Smith talks with Dr. Suma Babu about a newly approved treatment for ALS that is associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Read the related article on the <a href= "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-trea ...

  Show more

 . 19min 7sec